Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-Hydroxybutyrate Infusion in Heart Failure
NCT03560323Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Jan 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 3-hydroxybutyrate in heart failure (HF) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by UT Health San Antonio. Primary endpoints: Cardiac Output at 180 minutes, Ejection Fraction at 180 minutes and 1 more. Started Jan 2019; status: completed.
02
Drugs
3-hydroxybutyrate
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03560323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560323.